Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05998863 · ClinicalTrials.gov registry record · Phase 3

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

A Phase 3 study of Osteoporosis and Hypomagnesemia, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 3
Development phase
56
Enrollment target
2
Study locations

NCT05998863 is a Phase 3 study of Osteoporosis and Hypomagnesemia that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 56 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05998863, a Phase 3 study of Osteoporosis and Hypomagnesemia, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 3
Development phase
56 participants
Enrollment target
2
Study locations

Study Summary

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).

Conditions Studied

Osteoporosis Hypomagnesemia

Interventions

  • OTHER Placebo
  • DRUG EffCaMgCit

Study Locations (2)

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2024-04-19
Est. Completion 2026-12-31
Phase Phase 3

Sponsor

University of Texas Southwestern Medical Center

837 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05998863

The ClinicalTrials.gov registry entry for NCT05998863 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05998863 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05998863 about?

NCT05998863 is a clinical study titled "EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy". Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteop...

What is the current status of trial NCT05998863?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2024-04-19. Estimated completion is 2026-12-31.

What conditions does trial NCT05998863 study?

This clinical trial studies the following conditions: Osteoporosis, Hypomagnesemia.

What interventions are being tested in trial NCT05998863?

The interventions under investigation include: Placebo (OTHER), EffCaMgCit (DRUG).

Who is sponsoring clinical trial NCT05998863?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05998863 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoporosis

All registered trials for this condition

Hypomagnesemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.